A comparison of the ability of the human IgG1 allotypes G1m3 and G1m1, 17 to stimulate T-cell responses from allotype matched and mismatched donors. Issue 2 (17th February 2016)

• Record Type: Journal Article
• Authors: Webster, Carl I.; Bryson, Christine J.; Cloake, Edward A.; Jones, Tim D.; Austin, Mark J.; Karle, Anette C.; Spindeldreher, Sebastian; Lowe, David C.; Baker, Matthew P.
• Is Part Of: MAbs. Volume 8:Issue 2(2016)
• Page Start: 253
• Page End: 263
• Publication Date: 2016-02-17
• Subjects: Allotype -- Epitope -- HLA -- IgG -- Immunogenicity -- MAPPs -- MHC -- T-cell; Monoclonal antibodies -- Therapeutic use -- Periodicals; Monoclonal antibodies -- Periodicals; Antibodies, Monoclonal -- Periodicals; 616.0798
• DOI: 10.1080/19420862.2015.1128605
• Languages: English
• ISSNs: 1942-0862

Abstract

ABSTRACT: The immunogenicity of clinically administered antibodies has clinical implications for the patients receiving them, ranging from mild consequences, such as increased clearance of the drug from the circulation, to life-threatening effects. The emergence of methods to engineer variable regions resulting in the generation of humanised and fully human antibodies as therapeutics has reduced the potential for adverse immunogenicity. However, due to differences in sequence referred to as allotypic variation, antibody constant regions are not homogeneous within the human population, even within sub-classes of the same immunoglobulin isotype. For therapeutically administered antibodies, the potential exists for an immune response from the patient to the antibody if the allotype of patient and antibody do not match. Allotypic distribution in the human population varies within and across ethnic groups making the choice of allotype for a therapeutic antibody difficult. This study investigated the potential of human IgG1 allotypes to stimulate responses in human CD4 + T cells from donors matched for homologous and heterologous IgG1 allotypes. Allotypic variants of the therapeutic monoclonal antibody trastuzumab were administered to genetically defined allotypic matched and mismatched donor T cells. No significant responses were observed in the mismatched T cells. To investigate the lack of T-cell responses in relation to mismatched allotypes, HLA-DR agretopes were identified via MHC associated peptide proteomics (MAPPs). As expected, many HLA-DR restricted peptides were presented. However, there were no peptides presented from the sequence regions containing the allotypic variations. Taken together, the results from the T-cell assay and MAPPs assay indicate that the allotypic differences in human IgG1 do not represent a significant risk for induction of immunogenicity.